平安医药及医疗器械创新ETF(516820)资产负债表
|
2025-06-30 |
2024-12-31 |
2024-06-30 |
2023-12-31 |
资产 |
银行存款 |
- |
- |
- |
- |
结算备付金 |
1,409,375.38 |
33,797,299.75 |
30,557,586.40 |
521,251.05 |
存出保证金 |
327,438.67 |
297,179.87 |
158,438.54 |
345,726.11 |
交易性金融资产 |
1,462,098,051.91 |
1,621,320,466.14 |
1,107,601,416.89 |
1,198,671,862.00 |
其中:股票投资 |
1,462,098,051.91 |
1,621,320,466.14 |
1,107,601,416.89 |
1,198,671,862.00 |
债券投资 |
- |
- |
- |
- |
资产支持证券投资 |
- |
- |
- |
- |
衍生金融资产 |
- |
- |
- |
- |
买入返售金融资产 |
- |
- |
- |
- |
应收证券清算款 |
446,727.53 |
- |
565,209.35 |
412,631.96 |
应收利息 |
- |
- |
- |
- |
应收股利 |
- |
- |
314,174.02 |
- |
应收申购款 |
- |
- |
- |
- |
其他资产 |
75,616.24 |
91,049.16 |
1,392,566.78 |
37,753.68 |
资产总计 |
1,494,438,228.84 |
1,667,958,675.74 |
1,175,621,502.08 |
1,229,278,744.74 |
负 债 |
短期借款 |
- |
- |
- |
- |
交易性金融负债 |
- |
- |
- |
- |
衍生金融负债 |
- |
- |
- |
- |
卖出回购金融资产款 |
- |
- |
- |
- |
应付证券清算款 |
- |
3,873,615.92 |
- |
- |
应付赎回款 |
- |
- |
- |
- |
应付管理人报酬 |
603,991.56 |
733,156.39 |
476,788.52 |
515,436.72 |
应付托管费 |
120,798.32 |
146,631.29 |
95,357.70 |
103,087.34 |
应付销售服务费 |
- |
- |
- |
- |
应付交易费用 |
- |
- |
- |
- |
应交税费 |
- |
- |
6,349.87 |
- |
应付利息 |
- |
- |
- |
- |
应付利润 |
- |
- |
- |
- |
其他负债 |
1,736,781.46 |
2,641,262.66 |
3,357,204.46 |
3,001,880.31 |
负债合计 |
2,461,571.34 |
7,394,666.26 |
3,935,700.55 |
3,620,404.37 |
所有者权益 |
实收基金 |
4,259,415,249.00 |
4,953,415,249.00 |
3,777,415,249.00 |
2,990,415,249.00 |
未分配利润 |
-2,767,438,591.50 |
-3,292,851,239.52 |
-2,605,729,447.47 |
-1,764,756,908.63 |
所有者权益合计 |
1,491,976,657.50 |
1,660,564,009.48 |
1,171,685,801.53 |
1,225,658,340.37 |
负债及所有者权益总计 |
1,494,438,228.84 |
1,667,958,675.74 |
1,175,621,502.08 |
1,229,278,744.74 |